PT - JOURNAL ARTICLE AU - Elizabeth R. Lusczek AU - Nicholas E. Ingraham AU - Basil S. Karam AU - Jennifer Proper AU - Lianne Siegel AU - Erika S. Helgeson AU - Sahar Lotfi-Emran AU - Emily J. Zolfaghari AU - Emma Jones AU - Michael G. Usher AU - Jeffrey G. Chipman AU - R. Adams Dudley AU - Bradley Benson AU - Genevieve B. Melton AU - Anthony Charles AU - Monica I. Lupei AU - Christopher J. Tignanelli TI - Characterizing COVID-19 Clinical Phenotypes and Associated Comorbidities and Complication Profiles AID - 10.1101/2020.09.12.20193391 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.12.20193391 4099 - http://medrxiv.org/content/early/2020/09/14/2020.09.12.20193391.short 4100 - http://medrxiv.org/content/early/2020/09/14/2020.09.12.20193391.full AB - Background There is limited understanding of heterogeneity in outcomes across hospitalized patients with coronavirus disease 2019 (COVID-19). Identification of distinct clinical phenotypes may facilitate tailored therapy and improve outcomes.Objective Identify specific clinical phenotypes across COVID-19 patients and compare admission characteristics and outcomes.Design, Settings, and Participants Retrospective analysis of 1,022 COVID-19 patient admissions from 14 Midwest U.S. hospitals between March 7, 2020 and August 25, 2020.Methods Ensemble clustering was performed on a set of 33 vitals and labs variables collected within 72 hours of admission. K-means based consensus clustering was used to identify three clinical phenotypes. Principal component analysis was performed on the average covariance matrix of all imputed datasets to visualize clustering and variable relationships. Multinomial regression models were fit to further compare patient comorbidities across phenotype classification. Multivariable models were fit to estimate the association between phenotype and in-hospital complications and clinical outcomes.Main outcomes and measures Phenotype classification (I, II, III), patient characteristics associated with phenotype assignment, in-hospital complications, and clinical outcomes including ICU admission, need for mechanical ventilation, hospital length of stay, and mortality.Results The database included 1,022 patients requiring hospital admission with COVID-19 (median age, 62.1 [IQR: 45.9-75.8] years; 481 [48.6%] male, 412 [40.3%] required ICU admission, 437 [46.7%] were white). Three clinical phenotypes were identified (I, II, III); 236 [23.1%] patients had phenotype I, 613 [60%] patients had phenotype II, and 173 [16.9%] patients had phenotype III.When grouping comorbidities by organ system, patients with respiratory comorbidities were most commonly characterized by phenotype III (p=0.002), while patients with hematologic (p<0.001), renal (p<0.001), and cardiac (p<0.001) comorbidities were most commonly characterized by phenotype I. The adjusted odds of respiratory (p<0.001), renal (p<0.001), and metabolic (p<0.001) complications were highest for patients with phenotype I, followed by phenotype II. Patients with phenotype I had a far greater odds of hepatic (p<0.001) and hematological (p=0.02) complications than the other two phenotypes. Phenotypes I and II were associated with 7.30-fold (HR: 7.30, 95% CI: (3.11-17.17), p<0.001) and 2.57-fold (HR: 2.57, 95% CI: (1.10-6.00), p=0.03) increases in the hazard of death, respectively, when compared to phenotype III.Conclusion In this retrospective analysis of patients with COVID-19, three clinical phenotypes were identified. Future research is urgently needed to determine the utility of these phenotypes in clinical practice and trial design.Competing Interest StatementThe authors have declared no competing interest.Funding Statement1.NIH NHLBI T32HL07741 (NEI) 2.This research was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI) grant K12HS026379 (CJT) and the National Institutes of Health National Center for Advancing Translational Sciences grant KL2TR002492 and UL1TR002494. 3.NIH NHLBI T32HL129956 (JP LS) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Minnesota institutional review board (STUDY00001489).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available.